会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • Assays and therapies for latent viral infection
    • 潜伏病毒感染的检测和疗法
    • US20060257427A1
    • 2006-11-16
    • US11405355
    • 2006-04-17
    • John HarleyJudith JamesKenneth Kaufman
    • John HarleyJudith JamesKenneth Kaufman
    • A61K39/25A61K39/245
    • C07K14/005A61K39/00A61K39/12A61K39/245A61K2039/545A61K2039/55566C07K16/085C12N2710/16222C12N2710/16234Y02A50/386Y02A50/414
    • Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, which are conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for removal of the infected cells. These antibodies are capable of distinguishing cells expressing EBV DNA from cells which are not expressing EBV DNA. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also disclosed. The antibody conjugates can be used in diagnostic assays to identify cells expressing latent viral protein and people who are harboring latent viral particles. The antibody conjugates can also be used to remove the infected cells or to kill the infected the cells. Alternatively, or in addition, the viral proteins or portions thereof can be used as a vaccine to induce an immune reaction by the host to kill the infected cells. These methods can be used to detect or treat patients harboring latent viruses like EBV and who are at risk of developing a disease such as an autoimmune disease like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
    • 公开了结合在病毒生命周期的潜在阶段中特异性表达的病毒蛋白质的组合物。 这些组合物结合潜在的病毒蛋白质,同时病毒蛋白质在其细胞宿主中表达,并提供靶向隐藏潜伏病毒的细胞的手段。 在优选的实施方案中,组合物是结合潜伏病毒蛋白质的细胞外区域,最优选LMP-2A,EBV潜伏蛋白的抗体,其与诊断性或细胞毒性剂缀合或固定在固体支持物上以去除感染的 细胞。 这些抗体能够区分表达EBV DNA的细胞与不表达EBV DNA的细胞。 还可以公开可用于引发这些抗体或疫苗生产的组合物。 还公开了用于产生诊断或细胞毒素试剂和基于鉴定携带潜伏病毒的细胞的病毒表位的疫苗的方法。 抗体缀合物可用于诊断测定以鉴定表达潜伏性病毒蛋白的细胞和携带潜伏病毒颗粒的人。 抗体缀合物也可用于去除被感染的细胞或杀死被感染的细胞。 或者或另外,病毒蛋白质或其部分可以用作疫苗以诱导宿主杀死受感染细胞的免疫反应。 这些方法可用于检测或治疗患有EBV等潜伏病毒的患者,以及患有诸如系统性红斑狼疮(SLE)和类风湿性关节炎(RA)等自身免疫性疾病的疾病的风险。
    • 7. 发明申请
    • Assays and therapies for latent viral infection
    • US20060257428A1
    • 2006-11-16
    • US11405365
    • 2006-04-17
    • John HarleyJudith JamesKenneth Kaufman
    • John HarleyJudith JamesKenneth Kaufman
    • A61K39/25A61K39/245
    • A61K39/245A61K39/12A61K2039/545A61K2039/55566A61K2039/57C07K14/005C07K16/085C12N2710/16222C12N2710/16234
    • Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, which are conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for removal of the infected cells. These antibodies are capable of distinguishing cells expressing EBV DNA from cells which are not expressing EBV DNA. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also disclosed. The antibody conjugates can be used in diagnostic assays to identify cells expressing latent viral protein and people who are harboring latent viral particles. The antibody conjugates can also be used to remove the infected cells or to kill the infected the cells. Alternatively, or in addition, the viral proteins or portions thereof can be used as a vaccine to induce an immune reaction by the host to kill the infected cells. These methods can be used to detect or treat patients harboring latent viruses like EBV and who are at risk of developing a disease such as an autoimmune disease like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
    • 9. 发明申请
    • Assays and therapies for latent viral infection
    • 潜伏病毒感染的检测和疗法
    • US20050074751A1
    • 2005-04-07
    • US10646132
    • 2003-08-22
    • John HarleyJudith JamesKenneth Kaufman
    • John HarleyJudith JamesKenneth Kaufman
    • C12Q1/02A61K38/00A61K39/00A61K39/12A61K39/245A61K39/395A61K45/00A61P1/00A61P1/04A61P1/18A61P3/10A61P5/14A61P7/04A61P7/06A61P9/00A61P11/06A61P13/12A61P15/00A61P17/00A61P17/14A61P19/02A61P21/00A61P21/04A61P25/00A61P29/00A61P31/22A61P35/00A61P37/08C07K14/05C07K16/08C12Q1/70A61K39/42
    • C07K14/005A61K39/00A61K39/12A61K39/245A61K2039/545A61K2039/55566C07K16/085C12N2710/16222C12N2710/16234Y02A50/386Y02A50/414
    • Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, which are conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for removal of the infected cells. These antibodies are capable of distinguishing cells expressing EBV DNA from cells which are not expressing EBV DNA. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also disclosed. The antibody conjugates can be used in diagnostic assays to identify cells expressing latent viral protein and people who are harboring latent viral particles. The antibody conjugates can also be used to remove the infected cells or to kill the infected the cells. Alternatively, or in addition, the viral proteins or portions thereof can be used as a vaccine to induce an immune reaction by the host to kill the infected cells. These methods can be used to detect or treat patients harboring latent viruses like EBV and who are at risk of developing a disease such as an autoimmune disease like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
    • 公开了结合在病毒生命周期的潜在阶段中特异性表达的病毒蛋白质的组合物。 这些组合物结合潜在的病毒蛋白质,同时病毒蛋白质在其细胞宿主中表达,并提供靶向隐藏潜伏病毒的细胞的手段。 在优选的实施方案中,组合物是结合潜伏病毒蛋白质的细胞外区域,最优选LMP-2A,EBV潜伏蛋白的抗体,其与诊断性或细胞毒性剂缀合或固定在固体支持物上以去除感染的 细胞。 这些抗体能够区分表达EBV DNA的细胞与不表达EBV DNA的细胞。 还可以公开可用于引发这些抗体或疫苗生产的组合物。 还公开了用于产生诊断或细胞毒素试剂和基于鉴定携带潜伏病毒的细胞的病毒表位的疫苗的方法。 抗体缀合物可用于诊断测定以鉴定表达潜伏性病毒蛋白的细胞和携带潜伏病毒颗粒的人。 抗体缀合物也可用于去除被感染的细胞或杀死被感染的细胞。 或者或另外,病毒蛋白质或其部分可以用作疫苗以诱导宿主杀死受感染细胞的免疫反应。 这些方法可用于检测或治疗患有EBV等潜伏病毒的患者,以及患有诸如系统性红斑狼疮(SLE)和类风湿性关节炎(RA)等自身免疫性疾病的疾病的风险。